Developer docs
API playgroundTry for free, no card

Search company profiles

Future Diagnostics

Full company profile

uuid000efmi

Namestring
Future Diagnostics
Legal namestring
Future Diagnostic Solutions B.V.
Company typeenum
Private
Founded yearint
1997
Descriptiontext

Future Diagnostic Solutions B.V. (operating as Future Diagnostics or FDX) is a Netherlands-based contract development and manufacturing organization (CDMO) founded in 1997 and headquartered in Wijchen. The company delivers end-to-end in-vitro diagnostic (IVD) assay development services to biotech, pharmaceutical, and diagnostic companies worldwide. Its service portfolio spans the full development lifecycle — proof-of-concept, feasibility, design, optimization, verification, validation, pilot production, and tech transfer — across immunoassay formats including ELISA, chemiluminescence (CLIA), fluorescence (FIA), multiplex microarray, point-of-care, and turbidimetric immunoassays. Beyond development, Future Diagnostics operates a CDMO manufacturing arm offering bead coating, bioconjugation, lyophilization (including Accusphere technology), and contract manufacturing within an ISO 13485-certified facility. A key technical differentiator is the proprietary micro-SCY™ antibody screening platform, which the company claims delivers faster convergence on optimal antibody-antigen matches and reduced trial-and-error in assay development. The company also operates on-site automated clinical analyzers (Abbott Architect, Abbott Alinity, Beckman Coulter DxI 600) for comparison studies and method validation.

The business model is project-based professional services delivered through Statements of Work (SOW) with milestone-based payments, paired with managed-services contract manufacturing. Pricing is not publicly disclosed; each project is scoped individually, and compensation is indexed to supplier tariffs, wages, taxes, transport costs, and other surcharges, with annual price adjustments. The company's standard liability cap is €250,000 per SOW, and contracts are typically multi-year. GTM motion is sales-led and direct B2B, targeting three primary vertical segments: diagnostic companies, pharmaceutical companies (with a dedicated Biomarkers & Pharma-Related IVDs offering focused on companion diagnostics), and biotech companies. The company markets itself through technical blog content, peer-reviewed publications and posters (including a 2024 micro-SCY™ poster), case studies, and industry event participation. Quality systems are embedded across the offering: ISO 13485 registration, IVDR compliance, FDA QSR compliance, and GDPR-compliant data handling. The company claims 25+ years of specialized IVD immunoassay expertise (also stated as 28 years elsewhere), hundreds of successful assays delivered worldwide, and named-customer relationships with global multinationals including Abbott, Beckman Coulter, BioMérieux, Bio-Rad, Siemens Healthineers, Philips, Canon Medical Systems, Ortho-Clinical Diagnostics, Volition, and Tecan. Leadership includes Frank B. Martel (Managing Director) and Ernst Lindhout (Head of Research and Science).

Short descriptiontext

Future Diagnostics is a Netherlands-based CDMO founded in 1997 that provides end-to-end IVD immunoassay development, validation, and small-to-medium scale manufacturing services to biotech, pharmaceutical, and diagnostic companies worldwide, differentiated by its proprietary micro-SCY™ antibody screening platform.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersUden, Netherlands
HQ citystring
Uden
HQ countrystring
Netherlands
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
IVD assay development, immunoassay development services, contract diagnostics manufacturing, biomarker assay development, point-of-care test development
Industry4 codes
PRIMARYHLAHAAAM
IVD Reagents, Assay Kits & Consumables (Non-instrument)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAAAMAL
Biomarker Assay & Reagent Development (LDT/IVD assay design, antibodies/standards/controls)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAGABAK
Clinical Trial Material (CTM) Manufacturing & Supply CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAAAMAB
Companion Diagnostic (CDx) Co-Development Services (biopharma partnerships, clinical strategy)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
NAICS code3 codes
  • In-Vitro Diagnostic Substance Manufacturing325413
  • Medical and Diagnostic Laboratories62151
  • Medical Equipment and Supplies Manufacturing3391
SIC code3 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Services-Medical Laboratories8071
  • Services-Testing Laboratories8734
Product category
In Vitro Diagnostics Contract Development & Manufacturing
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Contract IVD Assay Development Services
TypeProfessional Services
Description

Project-based professional services for IVD assay development, covering proof-of-concept, feasibility, design, verification, validation, and tech transfer phases. Revenue is generated through Statement of Work (SOW) agreements with milestone-based payments. Services include custom assay development, optimization of existing assays, and verification & validation studies.

future-diagnostics.com
2CDMO Manufacturing Services
TypeManaged Services
Description

Contract manufacturing and reagent services including bead coating, conjugation, lyophilization, and micro-SCY services. Small to medium scale manufacturing for assay components and finished products. Revenue generated through manufacturing agreements with clients.

future-diagnostics.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain, Marketing or Sales
Pricing details1 tier
1Custom project-based pricing based on scope, timeline, and complexity
ModelOtherBilling cadenceMulti-year contract
Notes

Each project is scoped individually through a Statement of Work (SOW). Compensation includes milestone payments tied to project deliverables. The company conducts annual price adjustments based on cost elements. No public pricing tiers or rate cards available.

future-diagnostics.com
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 record
1micro-SCY™
Description

Proprietary antibody screening platform for unmatched antibody screening insights, delivering faster convergence on optimal antibody-antigen matches and reduced trial-and-error

future-diagnostics.com
Core offering1 text field

Future Diagnostics (FDX) is a Contract Development and Manufacturing Organization (CDMO) delivering end-to-end in-vitro diagnostic (IVD) assay development services to biotech, pharma, and diagnostic companies. Its portfolio spans immunoassay development (ELISA, FIA, CLIA, microarray, turbidimetric), point-of-care tests, automated immunoassay analyzers, verification & validation, IVDR performance evaluation studies, and small-to-medium scale ISO 13485 contract manufacturing including bead coating, conjugation, and lyophilization. The proprietary micro-SCY™ platform provides differentiated antibody screening capabilities to accelerate assay development.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Hundreds of successful assays delivered worldwide
+1 more record
Product overview1 text field

Future Diagnostics (FDX) is a CDMO (Contract Development and Manufacturing Organization) offering end-to-end IVD assay development services, not a software product company. Its portfolio is organized into two main divisions: IVD Assay Development Services and CDMO Manufacturing Services. The IVD services span assay types including ELISA/immunoassays, multiplex microarrays, point-of-care tests, and automated immunoassay analyzers — all supported by verification & validation, performance evaluation studies (IVDR), and comparison studies on automated platforms. The CDMO arm covers contract manufacturing and reagent services (bead coating, conjugation, lyophilization). A key differentiator is the proprietary micro-SCY™ platform for accelerated antibody screening. FDX serves biotech, pharma, and diagnostic companies from proof-of-concept through commercialization, with in-house ISO 13485 and FDA-registered manufacturing capabilities.

Product and service1 record
1IVD Assay Development Services
Scale indicator4 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Mercodia is a Swedish CDMO specializing in IVD immunoassay development and manufacturing, with deep expertise in ELISA and clinical immunoassays. It is the closest direct peer to Future Diagnostics in terms of service model, customer base (pharma and diagnostic companies), and technology focus.

TypeDirect peer
Description

Surmodics provides IVD contract manufacturing and reagent components, including bio-conjugation, antibody stabilization, and assay components. It overlaps directly with Future Diagnostics' CDMO services in bead coating, conjugation, and lyophilization.

TypeDirect peer
Description

Bio-Techne manufactures proteins, antibodies, and immunoassay development reagents serving the diagnostics and life sciences markets. It is comparable to Future Diagnostics' biomarker assay and reagent development services for biotech and pharma customers.

TypeDirect peer
Description

Meridian Bioscience develops, manufactures, and markets diagnostic test kits and reagents for infectious disease and other conditions. It competes in IVD assay development and manufacturing for similar clinical diagnostic customers.

TypeBroad incumbent
Description

Eurofins is a global contract testing and CDMO network with significant IVD and life sciences testing services. While broader in scope than Future Diagnostics, it competes for similar biotech and diagnostic validation work and has much greater scale.

TypeBroad incumbent
Description

Charles River provides CDMO and CRO services across biologics, diagnostics, and life sciences research. It overlaps with Future Diagnostics in assay development and contract manufacturing for diagnostic and pharma clients.

TypeBroad incumbent
Description

DiaSorin is an Italian IVD company that develops and manufactures immunoassay kits and automated platforms. It is a larger, vertically integrated peer in IVD assay development for clinical diagnostics.

TypeBroad incumbent
Description

Thermo Fisher operates one of the largest life sciences CDMO and IVD reagent businesses globally. While far broader than Future Diagnostics, it competes for similar biotech and pharma assay development projects.

TypeEmerging player
Description

Quanterix develops ultra-sensitive single-molecule immunoassay technology and contract research services. It overlaps with Future Diagnostics in advanced immunoassay development, though with a more specialized platform focus.

TypeBroad incumbent
Description

Agilent provides analytical instruments, reagents, and contract laboratory services for life sciences and diagnostics. Its diagnostics and clinical market business overlaps with Future Diagnostics' IVD development services.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers16 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Future Diagnostics

In Vitro Diagnostics Contract Development & Manufacturingfuture-diagnostics.com

Future Diagnostics is a Netherlands-based CDMO founded in 1997 that provides end-to-end IVD immunoassay development, validation, and small-to-medium scale manufacturing services to biotech, pharmaceutical, and diagnostic companies worldwide, differentiated by its proprietary micro-SCY™ antibody screening platform.

What Future Diagnostics does

Future Diagnostic Solutions B.V. (operating as Future Diagnostics or FDX) is a Netherlands-based contract development and manufacturing organization (CDMO) founded in 1997 and headquartered in Wijchen. The company delivers end-to-end in-vitro diagnostic (IVD) assay development services to biotech, pharmaceutical, and diagnostic companies worldwide. Its service portfolio spans the full development lifecycle — proof-of-concept, feasibility, design, optimization, verification, validation, pilot production, and tech transfer — across immunoassay formats including ELISA, chemiluminescence (CLIA), fluorescence (FIA), multiplex microarray, point-of-care, and turbidimetric immunoassays. Beyond development, Future Diagnostics operates a CDMO manufacturing arm offering bead coating, bioconjugation, lyophilization (including Accusphere technology), and contract manufacturing within an ISO 13485-certified facility. A key technical differentiator is the proprietary micro-SCY™ antibody screening platform, which the company claims delivers faster convergence on optimal antibody-antigen matches and reduced trial-and-error in assay development. The company also operates on-site automated clinical analyzers (Abbott Architect, Abbott Alinity, Beckman Coulter DxI 600) for comparison studies and method validation.

The business model is project-based professional services delivered through Statements of Work (SOW) with milestone-based payments, paired with managed-services contract manufacturing. Pricing is not publicly disclosed; each project is scoped individually, and compensation is indexed to supplier tariffs, wages, taxes, transport costs, and other surcharges, with annual price adjustments. The company's standard liability cap is €250,000 per SOW, and contracts are typically multi-year. GTM motion is sales-led and direct B2B, targeting three primary vertical segments: diagnostic companies, pharmaceutical companies (with a dedicated Biomarkers & Pharma-Related IVDs offering focused on companion diagnostics), and biotech companies. The company markets itself through technical blog content, peer-reviewed publications and posters (including a 2024 micro-SCY™ poster), case studies, and industry event participation. Quality systems are embedded across the offering: ISO 13485 registration, IVDR compliance, FDA QSR compliance, and GDPR-compliant data handling. The company claims 25+ years of specialized IVD immunoassay expertise (also stated as 28 years elsewhere), hundreds of successful assays delivered worldwide, and named-customer relationships with global multinationals including Abbott, Beckman Coulter, BioMérieux, Bio-Rad, Siemens Healthineers, Philips, Canon Medical Systems, Ortho-Clinical Diagnostics, Volition, and Tecan. Leadership includes Frank B. Martel (Managing Director) and Ernst Lindhout (Head of Research and Science).

Future Diagnostics firmographics

Firmographics
Name
Future Diagnostics
Legal name
Future Diagnostic Solutions B.V.
Website
https://future-diagnostics.com
Company type
Private
Founded year
1997
Operating status
Operating
Headcount range
11–50 employees
Short description
Future Diagnostics is a Netherlands-based CDMO founded in 1997 that provides end-to-end IVD immunoassay development, validation, and small-to-medium scale manufacturing services to biotech, pharmaceutical, and diagnostic companies worldwide, differentiated by its proprietary micro-SCY™ antibody screening platform.
Ownership category
akta.pro rank

Future Diagnostics industry classification

Industry
Product category
In Vitro Diagnostics Contract Development & Manufacturing
NAICS
In-Vitro Diagnostic Substance Manufacturing (325413), Medical and Diagnostic Laboratories (62151), Medical Equipment and Supplies Manufacturing (3391)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071), Services-Testing Laboratories (8734)
akta.pro industry
PRIMARYHLAHAAAM
IVD Reagents, Assay Kits & Consumables (Non-instrument)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAAAMAL
Biomarker Assay & Reagent Development (LDT/IVD assay design, antibodies/standards/controls)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAGABAK
Clinical Trial Material (CTM) Manufacturing & Supply CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAAAMAB
Companion Diagnostic (CDx) Co-Development Services (biopharma partnerships, clinical strategy)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics

Keywords

  • IVD assay development
  • Immunoassay development services
  • Contract diagnostics manufacturing
  • Biomarker assay development
  • Point-of-care test development

Where Future Diagnostics is headquartered

Location

Headquarters

HQ city
Uden
HQ country
Netherlands
HQ region
Europe

Offices1 record

Markets served

Future Diagnostics business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain, Marketing or Sales

Revenue model

  1. Contract IVD Assay Development Services: Project-based professional services for IVD assay development, covering proof-of-concept, feasibility, design, verification, validation, and tech transfer phases. Revenue is generated through Statement of Work (SOW) agreements with milestone-based payments. Services include custom assay development, optimization of existing assays, and verification & validation studies.
  2. CDMO Manufacturing Services: Contract manufacturing and reagent services including bead coating, conjugation, lyophilization, and micro-SCY services. Small to medium scale manufacturing for assay components and finished products. Revenue generated through manufacturing agreements with clients.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractCustom project-based pricing based on scope, timeline, and complexity

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Future Diagnostics product offering

Product offering

Core offering

Future Diagnostics (FDX) is a Contract Development and Manufacturing Organization (CDMO) delivering end-to-end in-vitro diagnostic (IVD) assay development services to biotech, pharma, and diagnostic companies. Its portfolio spans immunoassay development (ELISA, FIA, CLIA, microarray, turbidimetric), point-of-care tests, automated immunoassay analyzers, verification & validation, IVDR performance evaluation studies, and small-to-medium scale ISO 13485 contract manufacturing including bead coating, conjugation, and lyophilization. The proprietary micro-SCY™ platform provides differentiated antibody screening capabilities to accelerate assay development.

Product overview

Future Diagnostics (FDX) is a CDMO (Contract Development and Manufacturing Organization) offering end-to-end IVD assay development services, not a software product company. Its portfolio is organized into two main divisions: IVD Assay Development Services and CDMO Manufacturing Services. The IVD services span assay types including ELISA/immunoassays, multiplex microarrays, point-of-care tests, and automated immunoassay analyzers — all supported by verification & validation, performance evaluation studies (IVDR), and comparison studies on automated platforms. The CDMO arm covers contract manufacturing and reagent services (bead coating, conjugation, lyophilization). A key differentiator is the proprietary micro-SCY™ platform for accelerated antibody screening. FDX serves biotech, pharma, and diagnostic companies from proof-of-concept through commercialization, with in-house ISO 13485 and FDA-registered manufacturing capabilities.

Differentiator

Problem solved

Functional benefit

Brands

  • micro-SCY™: Proprietary antibody screening platform for unmatched antibody screening insights, delivering faster convergence on optimal antibody-antigen matches and reduced trial-and-error

Products and services

  • IVD Assay Development Services

Quantifiable outcome

  • Hundreds of successful assays delivered worldwide
  • +1 more outcomes

Companies that use Future Diagnostics

Customer profile

Named customers16 records

Segments3 records

Ideal customer profiles2 records

Future Diagnostics technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Future Diagnostics partnerships and signals

Strategic signal

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Future Diagnostics competitors and assessment

Company assessment

Direct peers

  • Mercodia: Mercodia is a Swedish CDMO specializing in IVD immunoassay development and manufacturing, with deep expertise in ELISA and clinical immunoassays. It is the closest direct peer to Future Diagnostics in terms of service model, customer base (pharma and diagnostic companies), and technology focus.
  • Surmodics: Surmodics provides IVD contract manufacturing and reagent components, including bio-conjugation, antibody stabilization, and assay components. It overlaps directly with Future Diagnostics' CDMO services in bead coating, conjugation, and lyophilization.
  • Bio-Techne: Bio-Techne manufactures proteins, antibodies, and immunoassay development reagents serving the diagnostics and life sciences markets. It is comparable to Future Diagnostics' biomarker assay and reagent development services for biotech and pharma customers.
  • Meridian Bioscience: Meridian Bioscience develops, manufactures, and markets diagnostic test kits and reagents for infectious disease and other conditions. It competes in IVD assay development and manufacturing for similar clinical diagnostic customers.

Broad incumbents

  • Eurofins Scientific: Eurofins is a global contract testing and CDMO network with significant IVD and life sciences testing services. While broader in scope than Future Diagnostics, it competes for similar biotech and diagnostic validation work and has much greater scale.
  • Charles River Laboratories: Charles River provides CDMO and CRO services across biologics, diagnostics, and life sciences research. It overlaps with Future Diagnostics in assay development and contract manufacturing for diagnostic and pharma clients.
  • DiaSorin: DiaSorin is an Italian IVD company that develops and manufactures immunoassay kits and automated platforms. It is a larger, vertically integrated peer in IVD assay development for clinical diagnostics.
  • Thermo Fisher Scientific: Thermo Fisher operates one of the largest life sciences CDMO and IVD reagent businesses globally. While far broader than Future Diagnostics, it competes for similar biotech and pharma assay development projects.
  • Agilent Technologies: Agilent provides analytical instruments, reagents, and contract laboratory services for life sciences and diagnostics. Its diagnostics and clinical market business overlaps with Future Diagnostics' IVD development services.

Emerging players

  • Quanterix: Quanterix develops ultra-sensitive single-molecule immunoassay technology and contract research services. It overlaps with Future Diagnostics in advanced immunoassay development, though with a more specialized platform focus.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

Future Diagnostics social profiles

Digital presence

Future Diagnostics compliance and trust

Trust signal

Compliance4 records

Future Diagnostics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Future Diagnostics leadership team

Management profile

Number of profiles

Profiles2 records

Future Diagnostics funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Future Diagnostics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Future Diagnostics

What does Future Diagnostics do?

Future Diagnostics (FDX) is a Contract Development and Manufacturing Organization (CDMO) delivering end-to-end in-vitro diagnostic (IVD) assay development services to biotech, pharma, and diagnostic companies. Its portfolio spans immunoassay development (ELISA, FIA, CLIA, microarray, turbidimetric), point-of-care tests, automated immunoassay analyzers, verification & validation, IVDR performance evaluation studies, and small-to-medium scale ISO 13485 contract manufacturing including bead coating, conjugation, and lyophilization. The proprietary micro-SCY™ platform provides differentiated antibody screening capabilities to accelerate assay development.

Is Future Diagnostics a public or private company?

Future Diagnostics is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Future Diagnostics founded?

Future Diagnostics was founded in 1997. It employs 11 to 50 people.

Where is Future Diagnostics based?

Future Diagnostics is headquartered in Uden, Netherlands, in the Europe region.

How does Future Diagnostics make money?

Two revenue lines are on record. Contract IVD Assay Development Services are the primary driver. The others are CDMO Manufacturing Services.

Who are Future Diagnostics's main competitors?

Direct peers on record are Mercodia, Surmodics, Bio-Techne and Meridian Bioscience. Broad incumbents are Eurofins Scientific, Charles River Laboratories, DiaSorin, Thermo Fisher Scientific and Agilent Technologies. Quanterix is listed as an emerging player.

Does Future Diagnostics have an API?

No public API is recorded for Future Diagnostics.

What industry is Future Diagnostics in?

Future Diagnostics's product category is In Vitro Diagnostics Contract Development & Manufacturing. Its primary akta.pro industry code is HLAHAAAM, IVD Reagents, Assay Kits & Consumables (Non-instrument), with a secondary code of HLAAAMAL, Biomarker Assay & Reagent Development (LDT/IVD assay design, antibodies/standards/controls). Its NAICS code is 325413 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals